23
Mar
Mar
Key insights Orally Semaglutide didn’t late cognitive or purposeful decline in individuals with early Alzheimer’s illness. Two giant Section 3 trials independently achieved the identical unfavorable medical outcome. Semaglutide produced some adjustments in biomarkers, however these didn’t translate into measurable profit to the affected person. Security was broadly in step with the identified results of […]